Allergan Director Trevor Jones Sells 2,000 Shares (AGN)
Allergan (NYSE:AGN) Director Trevor Jones unloaded 2,000 shares of Allergan stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $89.78, for a total value of $179,560.00. Following the completion of the transaction, the director now directly owns 8,142 shares of the company’s stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of research firms have recently commented on AGN. Analysts at Zacks reiterated a “neutral” rating on shares of Allergan (NYSE:AGN) in a research note to investors on Monday. They now have a $93.00 price target on the stock. Separately, analysts at JMP Securities cut their price target on shares of Allergan (NYSE:AGN) from $115.00 to $110.00 in a research note to investors on Thursday, August 1st. They now have a “market outperform” rating on the stock.
Eleven equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $107.16.
Allergan (NYSE:AGN) traded down 0.36% on Tuesday, hitting $88.96. 1,048,352 shares of the company’s stock traded hands. Allergan has a 52 week low of $81.33 and a 52 week high of $116.45. The stock has a 50-day moving average of $89.77 and a 200-day moving average of $99.04. The company has a market cap of $26.408 billion and a price-to-earnings ratio of 28.72.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the previous year, the company posted $1.07 earnings per share. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. Analysts expect that Allergan will post $4.76 EPS for the current fiscal year.
Allergan, Inc, is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.